Boston Scientific’s WATCHMAN FLX LAAC device meets 24-month endpoint in study
The trial is designed to assess the safety and efficacy of the next-generation WATCHMAN FLX LAAC device to…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
22 Jul 21
The trial is designed to assess the safety and efficacy of the next-generation WATCHMAN FLX LAAC device to…
20 Jul 21
The randomised and international clinical trial will enroll around 400 patients at up to 80 centres across the…
19 Jul 21
The company received CE marking for its artificial heart as a bridge to transplant in December last year
19 Jul 21
The first patient was implanted in Italy, at Città di Lecce Hospital with a Bicarbon aortic mechanical valve
16 Jul 21
The combined entity will operate as HeartFlow Group with an estimated $400m in cash
16 Jul 21
The company has also acquired peripheral thrombectomy company Truvic Medical, in a stock-for-stock transaction
15 Jul 21
The first occluder with a metal-free, bioresorbable frame for the treatment of patients with clinically significant, isolated ASDs
09 Jul 21
The company will enroll up to 50 patients in the trial at up to 15 centres in the…
07 Jul 21
The company will recruit up to 40 patients with monomorphic VT of both ischemic and non-ischemic origin in…
05 Jul 21
The PIONEER IV clinical trial will recruit up to 2,540 patients suffering from any type of coronary heart…